Company profile for Dx&Vx

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

DX&Vx is a cutting-edge biotechnology company specializing in the development of innovative diagnostic solutions and advanced vaccines. With a strong focus on R&D, we are committed to addressing critical healthcare needs through the creation of high-quality diagnostic tools and next-generation vaccines that enhance disease prevention and treatment. At DX&Vx, we combine state-of-the-art technologies with scientific expertise to...
DX&Vx is a cutting-edge biotechnology company specializing in the development of innovative diagnostic solutions and advanced vaccines. With a strong focus on R&D, we are committed to addressing critical healthcare needs through the creation of high-quality diagnostic tools and next-generation vaccines that enhance disease prevention and treatment. At DX&Vx, we combine state-of-the-art technologies with scientific expertise to develop precision diagnostics that offer accurate, timely results. Our vaccine development aims to combat emerging infectious diseases and improve global health outcomes.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
South Korea
Address
Address
10F, 173, Digital-ro, Geumcheon-gu, Seoul (Gasan-dong, Elysian)
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Arvo

Arvo

Not Confirmed

envelop Contact Supplier

Arvo

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/avixgen-a-subsidiary-of-dxvx-signs-a-licensing-out-agreement-worth-usd-360-million-with-a-us-biotech-company-for-its-next-generation-drug-delivery-platform-acp-302531979.html

PR NEWSWIRE
18 Aug 2025

https://www.prnewswire.com/news-releases/dxvx-signs-usd-220-million-co-development-and-license-agreement-for-mrna-cancer-vaccine-with-us-biotech-company-302517318.html

PR NEWSWIRE
30 Jul 2025

https://www.prnewswire.com/news-releases/dxvx-accelerates-development-of-universal-covid-19-vaccine-302468125.html

PR NEWSWIRE
28 May 2025

https://www.prnewswire.com/news-releases/dxvx-presents-a-new-paradigm-for-next-generation-infectious-disease-response-with-the-development-of-a-universal-vaccine-302349039.html

PR NEWSWIRE
13 Jan 2025

https://www.prnewswire.com/news-releases/dxvx-selected-for-koreas-first-arpa-h-project-in-2024-focusing-on-room-temperature-and-extra-long-term-vaccine-storage-technology-302293977.html

PR NEWSWIRE
01 Nov 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty